Outlook Therapeutics, Inc. 8-K

What Happened
Outlook Therapeutics, Inc. filed an 8-K on June 16, 2026 announcing that the U.S. Food and Drug Administration acknowledged receipt of its resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg). The FDA designated the resubmission a Class 1 review, which triggers a 60-day review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026. The company included a press release dated June 16, 2026 as an exhibit to the filing.

Key Details

• Filing date: Form 8-K filed June 16, 2026 (press release included as Exhibit 99.1).
• Product: ONS-5010 (bevacizumab-vikg).
• Review classification: FDA designated the BLA resubmission as a Class 1 review (60-day review period).
• PDUFA goal date: July 29, 2026.

Why It Matters
This 8-K sets a clear regulatory timeline for Outlook Therapeutics — the FDA’s PDUFA goal date of July 29, 2026 is the target for the agency’s decision on the resubmitted BLA. For investors, the PDUFA date is a material near-term milestone to watch: the FDA’s action (approval, complete response, or other communication) could materially affect the company’s regulatory progress and next steps. Monitor company updates and FDA communications around the PDUFA date for definitive outcomes.